A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori | Zendy

Masahiro Tsujimae | Zendy; Hiroshi Yamashita | Zendy; Hiroki Hashimura | Zendy; Chise Kano | Zendy; Keiko Shimoyama | Zendy; Atsushi Kanamori | Zendy; Kunio Matsumoto | Zendy; Akio Koizumi | Zendy; Kenji Momose | Zendy; Takaaki Eguchi | Zendy; Takumi Fukuchi | Zendy; Mikio Fujita | Zendy; Akihiko Okada | Zendy

Open Access

A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori

Author(s) -

Masahiro Tsujimae,

Hiroshi Yamashita,

Hiroki Hashimura,

Chise Kano,

Keiko Shimoyama,

Atsushi Kanamori,

Kunio Matsumoto,

Akio Koizumi,

Kenji Momose,

Takaaki Eguchi,

Takumi Fukuchi,

Mikio Fujita,

Akihiko Okada

Publication year - 2016

Publication title -

digestion

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.882

H-Index - 75

eISSN - 1421-9867

pISSN - 0012-2823

DOI - 10.1159/000454762

Subject(s) - esomeprazole , helicobacter pylori , amoxicillin , clarithromycin , gastroenterology , medicine , omeprazole , metronidazole , rabeprazole , proton pump inhibitor , antibiotics , microbiology and biotechnology , biology

Helicobacter pylori eradication rates have decreased worldwide. Gastric acid inhibition during treatment is important to eradicate these bacteria successfully. A new potassium-competitive acid blocker, vonoprazan (VPZ), has been shown to achieve high eradication rates in a previous randomized controlled trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research